Product Data Sheet

SPR41

Target: SARS-CoV

Pathway: Anti-infection

Storage: Please store the product under the recommended conditions in the Certificate of

Analysis.

BIOLOGICAL ACTIVITY

Description	SPR41 is a potent SARS-CoV-2 main protease inhibitor with K_i values of 0.184, 0.252, 14.4 μ M for SARS-CoV-2 M^{pro} , hCatL, hCatB, respectively. SPR41 shows antiviral and cytotoxicity ^[1] .
IC ₅₀ & Target	K_i : 0.184 μM (SARS-CoV-2 M^{pro}); 0.252 μM (hCatL); 14.4 μM (hCatB) $^{[1]}$
In Vitro	SPR41 (0-100 μ M; 1 h) shows antiviral and cytotoxicity with EC ₅₀ of 1.8 μ M for SARS-CoV-2 infected Huh-7-ACE2 cells and CC $_{50}$ of 14.5 μ M for Huh-7-ACE2 cells ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Previti S, et al. Structure-based lead optimization of peptide-based vinyl methyl ketones as SARS-CoV-2 main protease inhibitors. Eur J Med Chem. 2022 Dec 15;247:115021.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA